UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network

Frontiers in psychiatry, 2021-05, Vol.12, p.640120-640120

2021

Volltextzugriff (PDF)

Adverse drug reaction monitoring: Doing it the French way – Act II

Therapie, 2021-09, Vol.76 (5), p.385-387

2021

Volltextzugriff (PDF)

Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022

CNS drugs, 2024-09, Vol.38 (9), p.743-751

2024

Volltextzugriff (PDF)

Cannabidiol and pharmacokinetics drug-drug interactions: Pharmacological toolbox

Therapie, 2024-05, Vol.79 (3), p.351-363

2024

Volltextzugriff (PDF)

Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor–induced angioedema: A disproportionality analysis of the WHO pharmacovigilance database

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2020-07, Vol.8 (7), p.2406-2408.e1

2020

Volltextzugriff (PDF)

Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions

Clinical pharmacology and therapeutics, 2021-08, Vol.110 (2), p.392-400

2021

Volltextzugriff (PDF)

What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?

Frontiers in pharmacology, 2022-04, Vol.13, p.883987-883987

2022

Volltextzugriff (PDF)

Antibiotic-induced neurological adverse drug reactions

Therapie, 2024-03, Vol.79 (2), p.181-188

2024

Volltextzugriff (PDF)

Serious Neurological Adverse Events of Ceftriaxone

Antibiotics (Basel), 2021-05, Vol.10 (5), p.540

2021

Volltextzugriff (PDF)

Antidepressants abuse in subjects with opioid use disorders: A 10‐year study in the French OPPIDUM program

Fundamental & clinical pharmacology, 2022-04, Vol.36 (2), p.436-442

2022

Volltextzugriff (PDF)

Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic

Therapie, 2022-05, Vol.77 (3), p.301-307

2022

Volltextzugriff (PDF)

Adverse drug reactions profiles for abiraterone and enzalutamide: A pharmacovigilance descriptive analysis

Therapie, 2021-09, Vol.76 (5), p.455

2021

Volltextzugriff (PDF)

Fabrication technologies implemented for the European test blanket modules: Status for HCPB and WCLL

Fusion engineering and design, 2021-03, Vol.164, p.112201, Article 112201

2021

Volltextzugriff (PDF)

Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network

Fundamental & clinical pharmacology, 2024-02, Vol.38 (5), p.978-987

2024

Volltextzugriff (PDF)

French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge

Therapie, 2021-07, Vol.76 (4), p.297-303

2021

Volltextzugriff (PDF)

Sex differences in adverse drug reactions: Are women more impacted?

Therapie, 2023-03, Vol.78 (2), p.175-188

2023

Volltextzugriff (PDF)

Innovative approaches in CNS clinical drug development: Quantitative systems pharmacology

Therapie, 2021-03, Vol.76 (2), p.111-119

2021

Volltextzugriff (PDF)

Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study

International journal of mental health and addiction, 2023-05

2023

Volltextzugriff (PDF)

Patients’ organizations in rare diseases and involvement in drug information: Illustrations with LMC France, the French Association of Chronic Myeloid leukemia

Therapie, 2020-04, Vol.75 (2), p.221-224

2020

Volltextzugriff (PDF)

Correction to: Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022

CNS drugs, 2024-10, Vol.38 (10), p.839-839

2024

Volltextzugriff (PDF)

Augmentation de l’abus de méthylphénidate : repérage et profils sur 13 années

Therapie, 2022-11, Vol.77 (6), p.713-721

2022

Volltextzugriff (PDF)

Augmentation des surdosages et des décès en lien avec la consommation de méthadone durant la crise sanitaire liée au COVID 19 au regard des tendances observées en 2019

Therapie, 2021-03, Vol.76 (2), p.171-171

2021

Volltextzugriff (PDF)

Augmentation de l’abus de méthadone chez les mineurs

Therapie, 2021-03, Vol.76 (2), p.157-157

2021

Volltextzugriff (PDF)

Différents profils d’usage de Méthylphénidate en population générale et importance de son abus : intérêt de la Méthode de classification à partir des bases de données de l’assurance maladie

Therapie, 2021-03, Vol.76 (2), p.175-175

2021

Volltextzugriff (PDF)

Augmentation de la consommation de cannabidiol dans l’enquête oppidum : qui sont les consommateurs en 2021 ?

Therapie, 2022-11, Vol.77 (6), p.768-769

2022

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(63)

Publikationsform

Sprache

Englisch
(52)
Französisch
(28)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(38)
Life Sciences
(22)
Humans
(19)
Pharmacology & Pharmacy
(16)
Pharmacology
(10)
Pharmacovigilance
(10)
Female
(9)
Cognitive Science
(8)
Male
(8)
Neuroscience
(8)
Toxicology
(8)
Addictovigilance
(7)
Adverse Drug Reaction Reporting Systems
(6)
Environmental Sciences
(6)
Environmental Sciences & Ecology
(6)
Animals
(5)
Drug Abuse
(5)
Human Health And Pathology
(5)
Mechanics
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network

Adverse drug reaction monitoring: Doing it the French way – Act II

Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022

Cannabidiol and pharmacokinetics drug-drug interactions: Pharmacological toolbox

Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor–induced angioedema: A disproportionality analysis of the WHO pharmacovigilance database

Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions

What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?

Antibiotic-induced neurological adverse drug reactions

Serious Neurological Adverse Events of Ceftriaxone

Antidepressants abuse in subjects with opioid use disorders: A 10‐year study in the French OPPIDUM program

Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic

Adverse drug reactions profiles for abiraterone and enzalutamide: A pharmacovigilance descriptive analysis

Fabrication technologies implemented for the European test blanket modules: Status for HCPB and WCLL

Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network

French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge

Sex differences in adverse drug reactions: Are women more impacted?

Innovative approaches in CNS clinical drug development: Quantitative systems pharmacology

Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study

Patients’ organizations in rare diseases and involvement in drug information: Illustrations with LMC France, the French Association of Chronic Myeloid leukemia

Correction to: Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022

Augmentation de l’abus de méthylphénidate : repérage et profils sur 13 années

Augmentation des surdosages et des décès en lien avec la consommation de méthadone durant la crise sanitaire liée au COVID 19 au regard des tendances observées en 2019

Augmentation de l’abus de méthadone chez les mineurs

Différents profils d’usage de Méthylphénidate en population générale et importance de son abus : intérêt de la Méthode de classification à partir des bases de données de l’assurance maladie

Augmentation de la consommation de cannabidiol dans l’enquête oppidum : qui sont les consommateurs en 2021 ?

Suchergebnisse filtern